#147 What place does IP strategy have in life sciences and AI? with Kevin Buckley - Founder
We have Kevin Buckley, Founder and CEO of Torrey Pines Law Group, PC in San Diego, USA. He joins us for an insightful chat on Life Sciences and AI.
Kevin grew up in San Diego but spent many years on the East Coast and Midwest as a partner in a large US law firm, leading the legal function of the largest US university related to its technology commercialization efforts, and helping bring a few therapeutics and medical devices to market. When complemented with his biotechnology law practice, he has assisted clients with translating and commercializing life-saving technologies throughout the world. He created Torrey Pines Law Group when he returned home to San Diego in 2013. Throughout his career, he has successfully represented pharmaceutical, biopharmaceutical, medical device, biotechnology, specialty chemical, digital health, healthcare software, artificial intelligence, and convergence technology clients for more than 20 years.
Enjoy the show!
Resources:
Kevin’s LinkedIn: https://www.linkedin.com/in/biotech-patent-attorney/
Torrey Pines Law Group on LinkedIn: https://www.linkedin.com/company/torrey-pines-law-group/
Quotes:
"If you got a patent on something you can’t detect the infringement of, then why get a patent in the first place, maybe keep it trade secret or as a small subset of trade secret law. Early on you need to decide what you want to do."
"IP does not exist in a vacuum. IP affects so many different other areas of law, business and science to some degree. Also, different laws, business and science also impact IP law, so it is completely integrated with every other facet of law."
"SaMD is an important thing to focus on and this is really the bread and butter when we work for data scientists."
Thanks to our sponsor:
And as always, we appreciate your Reviews, Follows, Likes, Shares and Ratings. It really helps new data scientists find us.
Thank you so much, and enjoy the show!